Core Viewpoint - Sichuan is focusing on high-quality development of the biopharmaceutical industry, aiming to establish itself as an innovation hub in Western China, with an emphasis on accelerating the transformation of scientific research achievements into accessible quality medicines for the public [1][3]. Group 1: Innovation and Regulatory Efficiency - The chairman of Sichuan Huiyu Pharmaceutical Co., Ding Zhao, highlighted the importance of efficient communication between enterprises and regulatory departments to expedite the approval process for new drugs [3]. - Ding proposed the establishment of a regional drug review center within the Chengdu-Chongqing economic circle to enhance the efficiency of drug approvals, which could significantly benefit local pharmaceutical companies [3]. - The establishment of the "Southwest Drug Review Center" is anticipated to be a major advantage for pharmaceutical enterprises in Sichuan and Chongqing by 2025 [3]. Group 2: Drug Pricing and Collection Policies - Ding emphasized the need to optimize drug collection policies to lower inflated drug prices, ensuring affordability for patients while maintaining the sustainability of medical insurance funds [3]. - The recent improvements in collection policies are seen as a positive development, balancing patient accessibility, insurance sustainability, and the innovation incentives for companies [3][4]. Group 3: Collaborative Innovation and Data Integration - Ding called for the government to lead efforts in integrating clinical data from research institutions and medical facilities to promote the deep integration of "artificial intelligence + medicine" [4]. - There is a push for better collaboration among research institutions, innovative pharmaceutical companies, and regulatory bodies to accelerate the transformation of innovative results into effective treatments [4]. - The expectation is that continuous policy innovation and systematic support will help Sichuan cultivate more globally competitive biopharmaceutical innovators [4].